Merck, Inc.
🇺🇸United States
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 159
- Registration Number
- NCT02252016
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Phase 3
Completed
- Conditions
- Head and Neck Squamous Cell Cancer
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 495
- Registration Number
- NCT02252042
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 291
- Registration Number
- NCT02226003
Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)
Phase 3
Completed
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: Prevnar 13™Biological: Pneumovax™ 23Biological: Placebo
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT02225587
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
Phase 3
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1274
- Registration Number
- NCT02220894
A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)
Phase 1
Completed
- Conditions
- HIV-1
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT02217904
A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)
Phase 1
Terminated
- Conditions
- Renal Cell Cancer
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 10
- Registration Number
- NCT02212730
Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)
Phase 3
Withdrawn
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT02204475
Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
Phase 2
Completed
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 399
- Registration Number
- NCT02203149
Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)
Not Applicable
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Device: Home telehealth system
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 500
- Registration Number
- NCT02194608
© Copyright 2025. All Rights Reserved by MedPath